April 15th, 2025
Hansoh Pharma (03692.HK) announces that, HS-10529 tablets, a small molecule category i innovative drug targeting KRAS G12D self-developed by the group, has obtained the clinical trial approval issued by the national medical products administration (nmpa) of china, which is intended to be investigated in clinical
trials for advanced solid tumors (pancreatic cancer, colorectal cancer, non-small cell lung cancer,
etc.) with KRAS G12D mutations.
